Clinical Trial Update: Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma

View source ↗

Summary

This clinical trial update notes that a study evaluating mepolizumab in patients with severe refractory eosinophilic asthma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Asthma

Drugs mentioned

• Nucala (mepolizumab)

Snippet

Sponsor: Istituti Clinici Scientifici Maugeri SpA | Conditions: Severe Eosinophilic Asthma | Status: COMPLETED